指南与共识膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌的保膀胱策略:国际膀胱癌小组的推荐

Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
指南 / 共识 · Eur Urol · 2025-04-22

国际膀胱癌小组组织全球专家委员会,通过文献回顾和改良德尔菲投票制定肌层浸润性膀胱癌保膀胱治疗推荐,最终推荐在2023年8月现场会议上达成≥75%共识。新诊断患者应在多学科环境中评估保膀胱治疗,主要替代方案为三联疗法,部分膀胱切除术或根治性经尿道切除术仅用于经过严格选择的患者。

要点

  • 新诊断肌层浸润性膀胱癌患者应在多学科环境中评估保膀胱治疗。
  • 三联疗法是根治性膀胱切除术的主要替代方案,有利预后因素包括单灶cT2期、无肾积水、无多灶原位癌。
  • 部分膀胱切除术或根治性经尿道切除术仅用于经过严格选择的患者。

核心结论

  • 国际膀胱癌小组共识推荐为肌层浸润性膀胱癌的保膀胱治疗提供了实践指导。

研究设计与样本

  • 组建全球膀胱癌专家委员会,工作组回顾文献并起草推荐,国际膀胱癌小组成员采用改良德尔菲流程投票。
  • 2023年8月现场会议展示投票结果和支持证据,推荐经讨论细化,最终推荐在现场会议上达成≥75%同意,并通过网络会议和电子邮件进一步细化。

主要发现

  • 新诊断肌层浸润性膀胱癌患者应接受多学科评估以考虑保膀胱治疗。
  • 根治性膀胱切除术的主要替代方案是三联疗法,三联疗法的有利预后因素包括单灶cT2期、无肾积水、无多灶原位癌。
  • 其他选项应保留给在充分权衡获益与风险后不适合或拒绝三联疗法或根治性膀胱切除术的极少数选择患者。
  • 这些选项包括对脐尿管腺癌行部分膀胱切除术,以及对可切除且切缘充分、无并存原位癌或组织学亚型的孤立肿瘤行部分膀胱切除术或仅根治性经尿道切除术。

关键数值与推荐

  • 新诊断肌层浸润性膀胱癌患者应接受多学科评估以考虑保膀胱治疗。
  • 三联疗法的有利预后因素包括单灶cT2期、无肾积水、无多灶原位癌。
  • 其他选项应保留给在充分权衡获益与风险后不适合或拒绝三联疗法或根治性膀胱切除术的极少数选择患者。
  • 对脐尿管腺癌可行部分膀胱切除术。
  • 对可切除且切缘充分、无并存原位癌或组织学亚型的孤立肿瘤可行部分膀胱切除术或仅根治性经尿道切除术。

临床怎么用

  • 新诊断肌层浸润性膀胱癌患者应在多学科环境中评估以考虑保膀胱治疗。
  • 三联疗法是根治性膀胱切除术的主要替代方案,有利预后因素包括单灶cT2期、无肾积水、无多灶原位癌。
  • 其他选项应保留给在充分权衡获益与风险后不适合或拒绝三联疗法或根治性膀胱切除术的极少数选择患者。
  • 对脐尿管腺癌可行部分膀胱切除术。
  • 对可切除且切缘充分、无并存原位癌或组织学亚型的孤立肿瘤可行部分膀胱切除术或仅根治性经尿道切除术。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Patient-centric management necessitates providing care aligned with patients' values, preferences, and expressed needs. Therefore, critical assessment of bladder preservation therapies (BPTs) as alternatives to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) and practical recommendations on the optimal selection of patients for BPTs are needed urgently. METHODS: A global committee of bladder cancer experts was assembled to develop BPT recommendations for MIBC. Working groups reviewed the literature and drafted recommendations, which were voted on by International Bladder Cancer Group (IBCG) members using a modified Delphi process. During a live meeting in August 2023, voting results and supporting evidence were presented, and recommendations were refined based on discussions. Final recommendations achieved ≥75% agreement during the meeting, with further refinements through web conferences and e-mail discussions. KEY FINDINGS AND LIMITATIONS: Patients with newly diagnosed MIBC should be offered evaluation in a multidisciplinary setting for consideration of BPTs. The main alternative to RC is trimodal therapy (TMT), and favorable prognostic factors for TMT include unifocal cT2 stage, lack of hydronephrosis, and no multifocal carcinoma in situ (CIS). Other options should be reserved for very select patients who are ineligible for or who decline TMT or RC after thorough consideration of benefits versus risks. These include partial cystectomy (PC) for urachal adenocarcinoma and PC or radical transurethral resection alone for solitary tumors amenable to resection with adequate margins and without concomitant CIS or histologic subtypes. CONCLUSIONS AND CLINICAL IMPLICATIONS: The IBCG consensus recommendations provide practical guidance on BPTs for MIBC.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gupta S, Hensley PJ, Li R, et al. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2025. PMID: 40268594. doi:10.1016/j.eururo.2025.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。